Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Experimental Tumor Clinical Trial

Official title: Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial

Status Recruiting

Clinical Trial Summary

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial

Clinical Trial Description

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients. ;

Related Conditions & MeSH terms

• Experimental Tumor
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral

• NCT number: NCT03617432
• Study type: Interventional
• Source: Peking University
• Contact: Jun Zhu, Dr.
• Phone: 010-88140650
• Email: dreaming2217@hotmai.com
• Status: Recruiting
• Phase: Phase 2
• Start date: August 28, 2018
• Completion date: September 30, 2022